SOURCE: Streetwise Reports

Streetwise Reports

February 04, 2016 09:00 ET

Cynata Therapeutics' Executive Chairman Stewart Washer Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - February 04, 2016) -  Cynata Therapeutics Ltd.(ASX: CYP) of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver.

The Life Sciences Report: Cynata Therapeutics is developing a proprietary platform for treating a wide range of diseases, including cancers. What sets your Cymerus platform technology apart in the field of regenerative medicine?

Stewart Washer: Cynata's technological breakthrough amps up our ability to manufacture mesenchymal stem cells (MSCs). MSCs are pluripotent stromal cells, the body's repair mechanism. They occur naturally in bone marrow, fat and other bodily tissues. When an injury occurs-from a cut finger to strokes and heart attacks-mesenchymal stem cells rush to the site of the injury. They release floods of growth factors and other goodies to calm down inflammation and catalyze cell repair and regrowth. These cellular superhealers are our body's first-aid kit, our first responders. But they can use some help.

For a dozen years, MSCs have been featured in a wide range of medical trials, often demonstrating success for treating lethal diseases. Clinical trials of MSCs are showing…

Continue reading this interview: Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


Cynata Therapeutics Ltd is a sponsor of Streetwise Reports. Stewart Washer had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Washer and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information